CGTX News and Press, Cognition Therapeutics Inc. From 06/23/22

Cognition Therapeutics (NASDAQ:CGTX) stock rose ~6% on June 23 after the company said the first patient was dosed in a phase 2 trial of oral drug CT1812 to treat patients with dementia with Lewy bodies (DLB). The company plans to enroll 120 adults between 50 and 80 years of age with a DL...

- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association - NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (Nasdaq: CGTX) today...

PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lisa Ricciardi , Cognition’s president and CEO will be presenting an update o...

PURCHASE, N.Y., June 02, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced plans to hold a virtual KOL symposium on June 9, 2022, from 10:00 - 11:30 a.m. ET to discuss dry age-related macular degeneration (dry AMD). Cognition plans to initiate a Phase 2 cli...

PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cog...

Cognition Therapeutics press release (NASDAQ:CGTX): Q1 GAAP EPS of $0.17 beats by $0.46. Cash and cash equivalents of $51.51M For further details see: Cognition Therapeutics GAAP EPS of $0.17 beats by $0.46

Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease Data Presented at Scientific Conferences Further Validate the Potential of σ-2 Modulators PURCHASE, N.Y., May 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeu...

PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of the release, the report date should be Wednesday, May 11, 2022, not Tuesday as previously sta...

PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “...

NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) , a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina, presented a poster today at the ann...